Publicaciones en las que colabora con Adolfo López de Munain Arregui (7)

2024

  1. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

    Science advances, Vol. 10, Núm. 41, pp. eadn6525

2021

  1. Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy

    Molecular Therapy - Nucleic Acids, Vol. 26, pp. 174-191

2019

  1. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 50, pp. 25203-25213

2016

  1. Six serum miRNAs fail to validate as myotonic dystrophy type 1 biomarkers

    PLoS ONE, Vol. 11, Núm. 2

2013

  1. Chromosome 16 consortium: Current developments on the characterization of the proteins encoded by the chromosome 16”

    Proteómica: revista de la Sociedad Española de Proteómica, Núm. 9, pp. 112-112

  2. Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients

    Human Molecular Genetics, Vol. 22, Núm. 4, pp. 704-716

2002

  1. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy

    Human Molecular Genetics, Vol. 11, Núm. 9, pp. 1119-1128